Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 6, 1998, Pages 747-753

  Maesaki, Shigefumi ^a   Marichal, Patrick ^b   Hossain, Mohammad Ashraf ^a   Sanglard, Dominique ^c   Bossche, Hugo Vanden ^b   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; PYRROLE DERIVATIVE; SODIUM AZIDE; TACROLIMUS; ANTIFUNGAL AGENT; CARRIER PROTEIN; CDR1 PROTEIN, CANDIDA ALBICANS; FUNGAL PROTEIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SACCHAROMYCES CEREVISIAE; AIDS RELATED COMPLEX; DRUG ANTAGONISM; DRUG EFFECT; GENE; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; THRUSH;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CANDIDIASIS, ORAL; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; FLUCONAZOLE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; GENES, MDR; HUMANS; ITRACONAZOLE; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; TACROLIMUS;

EID: 0032216576     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.6.747     Document Type: Article

References (24)

1. Marichal, P. & Vanden Bossche, H. (1995). Mechanisms of resistance to azole antifungals. Acta Biochimica Polonica 42, 509-16.
2. Vanden Bossche, H., Marichial, P. & Odds, F. C. (1994). Molecular mechanisms of drug resistance in fungi. Trends in Microbiology 2, 393-400.
3. Albertson, G. D., Niimi, M., Cannon, R. D. & Jenkinson, H. F. (1996). Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrobial Agents and Chemotherapy 40, 2835-41.
4. Goldway, M., Teff, D., Schmidt, R., Oppenheim, A. B. & Koltin, Y. (1995). Multiple resistance in Candida albicans: disruption of the BEN gene. Antimicrobial Agents and Chemotherapy 39, 422-6.
5. Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M. & Bille, J. (1995). Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrobial Agents and Chemotherapy 39, 2378-86.
6. Sanglard, D., Ischer, F., Monod, M. & Bille, J. (1996). Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Anti-microbial Agents and Chemotherapy 40, 2300-5.
7. Lamb, D. C., Kelly, D. E., Schunck, W. H., Shyadehi, A. Z., Akhtar, M., Lowe, D. J. et al. (1997). The mutation T315A in Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced activity. Journal of Biological Chemistry 272, 5682-8.
8. White, T. C. (1997). The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14α-demethylase in Candida albicans. Antimicrobial Agents and Chemotherapy 41, 1488-94.
9. Bellamy, W. T. (1996). P-glycoproteins and multidrug resistance. Annual Review of Pharmacology and Toxicology 36, 161-83.
10. Meyers, S., Schauer, W., Balzi, E., Wagner, M., Goffeau, A. & Golin, J. (1992). Interaction of the yeast pleiotropic drug resistance genes PDR1 and PDR5. Current Genetics 21, 431-6.
11. Leonard, P. J., Rathod, P. K. & Golin, J. (1994). Loss of function mutation in the yeast multiple drug resistance gene PDR5 causes a reduction in chloramphenicol efflux. Antimicrobial Agents and Chemotherapy 38, 2492-4.
12. Prasad, R., De Wergifosse, P., Goffeau, A. & Balzi, E. (1995). Molecular cloning and characterisation of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Current Genetics 27, 320-9.
13. Ross, D. D., Wooten, P. J., Sridhara, R., Ordonez, J. V., Lee, E. J. & Schiffer, C. A. (1993). Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 82, 1288-99.
14. Arceci, R. J., Stieglitz, K. & Bierer, B. E. (1992). Immuno-suppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 80, 1528-36.
15. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. & Komano, T. (1993). Human P-glycoprotein transports cyclosporin A and FK506. Journal of Biological Chemistry 268, 6077-80.
16. Yamaguchi, H., Uchida, K., Kume, H., Shinoda, T., Watanabe, K., Kusunoki, T. et al. (1994). Report of the committee of clinical laboratory standards. Japanese Journal of Medical Mycology 36, 61-86.
17. Marichal, P., Gorrens, J., Coene, M. C., LeJeune, L. & Vanden Bossche, H. (1995). Origin of differences in susceptibility of Candida krusei to azole antifungal agents. Mycoses 38, 111-7.
18. Ambudkar, S. V., Lelong, I. H., Zhang, J., Cardarelli, C. O., Gottesman, M. M. & Pastan, I. (1992). Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug stimulatable ATP hydrolysis. Proceedings of the National Academy of Sciences of the USA 89, 8472-6.
19. Abbaszadegan, M. R., Foley, N. E., Gleason Guzman, M. C. & Dalton, W. S. (1996). Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line. International Journal of Cancer 66, 506-14.
20. Broxterman, H. J., Pinedo, H. M., Kuiper, C. M., Kaptein, L. C. M., Schuurhuis, G. J. & Lankelman, J. (1988). Induction by verapamil of a rapid increase in ATP consumption in multidrug resistant tumor cells. FASEB Journal 2, 2278-82.
21. Laguna, F., Rodriguez Tudela, J. L., Martinez Suarez, J. V., Polo, R., Valencia, E., Diaz Guerra, T. M. et al. (1996). Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clinical Infectious Diseases 24, 124-30.
22. Fay, J. W., Wingard, J. R., Antin, J. H., Collins, R. H., Pineiro, L. A., Blazar, B. R. et al. (1996). FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood 87, 3514-9.
23. Nakagawa, H., Etoh, T., Yokota, Y., Ikeda, F., Hatano, K., Teratani, N. et al. (1996). Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patients with atopic dermatitis. Clinical Drug Investigation 12, 244-50.
24. Lam, H. H. & Althaus, B. L. (1995). Antifungal prophylaxis in bone marrow transplant. Annals of Pharmacotherapy 29, 921-4.